Vincent Xiang

Principal Managing Partner at 7G BioVentures
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Shanghai, China, CN

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • Venture Capital and Private Equity Principals
    • 1 - 100 Employee
    • Principal Managing Partner
      • Mar 2021 - Present

      Early Stage original disruptive innovation in the US and EU; world class team; large deal flow and top deal quality. Early Stage original disruptive innovation in the US and EU; world class team; large deal flow and top deal quality.

    • Mexico
    • Investment Banking
    • 1 - 100 Employee
    • Managing Director, Head of Global BioVentures
      • Jul 2018 - Mar 2021

      Led a team investing in cutting life science innovations on Global basis; Triaged thousands of projects; 8 board of directorship, over 80 deals, led 9. Led a team investing in cutting life science innovations on Global basis; Triaged thousands of projects; 8 board of directorship, over 80 deals, led 9.

    • Partner
      • Jun 2016 - Jun 2018

      Led 7 deals globally, team >40 deals globally; Leading from sourcing, DD, transaction, post deal alliance and management, and exits. Led 7 deals globally, team >40 deals globally; Leading from sourcing, DD, transaction, post deal alliance and management, and exits.

    • China
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Managing Director, Head of International M&A and BD
      • Feb 2013 - May 2016

      Built and Led the international M&D - BD team in US and China; Consummated a $500M LBO over a US specialty pharma, the largest ex-China acquisition by any China Pharma in 2016; Project BD sourcing, DD, negotiation, transaction, and post deal alliance. Built and Led the international M&D - BD team in US and China; Consummated a $500M LBO over a US specialty pharma, the largest ex-China acquisition by any China Pharma in 2016; Project BD sourcing, DD, negotiation, transaction, and post deal alliance.

    • Portfolio Manager and Senior Biotech Analyst
      • Apr 2004 - Dec 2012

      Led biotech investments on global basis as part of healthcare team; Ranked top percentile member in equity investment department. Led biotech investments on global basis as part of healthcare team; Ranked top percentile member in equity investment department.

Education

  • The Wharton School, UPenn
    Master of Business Administration - MBA, Healthcare Management
    1999 - 2023
  • Stony Brook University
    Doctor of Philosophy - PhD, Molecular Biology
    1994 - 1997
  • Fudan University
    B.S., Microbiology and Immunology
    1986 - 1990

Community

You need to have a working account to view this content. Click here to join now